Articles from Sanofi Winthrop Industrie

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program

Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia

Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease

AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors

Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation

 

Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1

Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study

Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes        

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease

Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Online availability of Sanofi’s half-year financial report for 2025

Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces extension of Blueprint tender offer

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

 

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

 

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Sanofi Launches 2025 Global Employee Stock Purchase Plan

ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs

Sanofi completes acquisition of DR-0201

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Annual General Meeting of April 30, 2025

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

Sanofi: strong Q1 performance and 2025 guidance confirmed

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

 

Chlamydia vaccine candidate granted fast track designation by the US FDA

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Sanofi successfully prices EUR 1.5 billion of bond issue